Published in Clin Infect Dis on October 01, 2011
Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med (2013) 4.26
The undiagnosed HIV epidemic in France and its implications for HIV screening strategies. AIDS (2014) 2.04
Estimating HIV Incidence, Time to Diagnosis, and the Undiagnosed HIV Epidemic Using Routine Surveillance Data. Epidemiology (2015) 1.83
HPTN 071 (PopART): a cluster-randomized trial of the population impact of an HIV combination prevention intervention including universal testing and treatment: mathematical model. PLoS One (2014) 1.66
HIV treatment as prevention: models, data, and questions--towards evidence-based decision-making. PLoS Med (2012) 1.62
Towards estimation of HIV-1 date of infection: a time-continuous IgG-model shows that seroconversion does not occur at the midpoint between negative and positive tests. PLoS One (2013) 1.04
Trends in AIDS Deaths, New Infections and ART Coverage in the Top 30 Countries with the Highest AIDS Mortality Burden; 1990-2013. PLoS One (2015) 1.02
How much is tuberculosis screening worth? Estimating the value of active case finding for tuberculosis in South Africa, China, and India. BMC Med (2014) 1.01
Should we treat acute HIV infection? Curr HIV/AIDS Rep (2012) 1.00
Evaluation of sequence ambiguities of the HIV-1 pol gene as a method to identify recent HIV-1 infection in transmitted drug resistance surveys. Infect Genet Evol (2013) 0.98
Has the rate of CD4 cell count decline before initiation of antiretroviral therapy changed over the course of the Dutch HIV epidemic among MSM? PLoS One (2013) 0.95
Global response to HIV: treatment as prevention, or treatment for treatment? Clin Infect Dis (2014) 0.94
A Comparison of South African National HIV Incidence Estimates: A Critical Appraisal of Different Methods. PLoS One (2015) 0.92
Closer to 90-90-90. The cascade of care after 10 years of ART scale-up in rural Malawi: a population study. J Int AIDS Soc (2016) 0.89
The increasing genetic diversity of HIV-1 in the UK, 2002-2010. AIDS (2014) 0.89
The potential impact of routine testing of individuals with HIV indicator diseases in order to prevent late HIV diagnosis. BMC Infect Dis (2013) 0.88
Cost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling study. PLoS One (2013) 0.88
Laboratory adverse events and discontinuation of therapy according to CD4(+) cell count at the start of antiretroviral therapy. AIDS (2014) 0.87
Symptomatic illness and low CD4 cell count at HIV seroconversion as markers of severe primary HIV infection. PLoS One (2013) 0.87
Estimating HIV incidence from case-report data: method and an application in Colombia. AIDS (2014) 0.85
Modeling the impact of interventions along the HIV continuum of care in Newark, New Jersey. Clin Infect Dis (2013) 0.85
Fractional Brownian motion and multivariate-t models for longitudinal biomedical data, with application to CD4 counts in HIV-positive patients. Stat Med (2015) 0.83
Time to eligibility for antiretroviral therapy in adults with CD4 cell count > 500 cells/μL in rural KwaZulu-Natal, South Africa. HIV Med (2015) 0.83
Early diagnosis and treatment of HIV infection: magnitude of benefit on short-term mortality is greatest in older adults. Age Ageing (2013) 0.83
Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria. AIDS (2015) 0.82
Late presentation to HIV testing is overestimated when based on the consensus definition. HIV Med (2015) 0.81
Slow immunological progression in HIV-1 CRF07_BC-infected injecting drug users. Emerg Microbes Infect (2013) 0.81
Increasing the use of second-line therapy is a cost-effective approach to prevent the spread of drug-resistant HIV: a mathematical modelling study. J Int AIDS Soc (2014) 0.81
Imputation of the Date of HIV Seroconversion in a Cohort of Seroprevalent Subjects: Implications for Analysis of Late HIV Diagnosis. AIDS Res Treat (2011) 0.80
CD4+ cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time. AIDS (2015) 0.78
Systematic review of HIV drug resistance in Southeast Asia. AIDS Rev (2013) 0.78
Treatment as prevention--where next? Curr HIV/AIDS Rep (2014) 0.78
The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials. HIV Clin Trials (2014) 0.77
Disease progression of HIV-1 infection in symptomatic and asymptomatic seroconverters in Osaka, Japan: a retrospective observational study. AIDS Res Ther (2015) 0.77
Optimal CD4 count for initiating HIV treatment: impact of CD4 observation frequency and grace periods, and performance of dynamic marginal structural models. Epidemiology (2014) 0.77
Oral lesions and immune status of HIV infected adults from eastern Nepal. J Clin Exp Dent (2013) 0.77
Update on HIV in Western Europe. Curr HIV/AIDS Rep (2014) 0.77
New indicators for delay in initiation of antiretroviral treatment: estimates for Cameroon. Bull World Health Organ (2015) 0.77
Mathematical modeling of HIV prevention measures including pre-exposure prophylaxis on HIV incidence in South Korea. PLoS One (2014) 0.76
Estimation and Short-Term Prediction of the Course of the HIV Epidemic Using Demographic and Health Survey Methodology-Like Data. PLoS One (2015) 0.76
Minimizing fungal disease deaths will allow the UNAIDS target of reducing annual AIDS deaths below 500 000 by 2020 to be realized. Philos Trans R Soc Lond B Biol Sci (2016) 0.75
Joint estimation of CD4+ cell progression and survival in untreated individuals with HIV-1 infection. AIDS (2017) 0.75
PrEP as a feature in the optimal landscape of combination HIV prevention in sub-Saharan Africa. J Int AIDS Soc (2016) 0.75
Optimizing HIV pre-exposure prophylaxis implementation among men who have sex with men in a large urban centre: a dynamic modelling study. J Int AIDS Soc (2016) 0.75
Partner Notification for Reduction of HIV-1 Transmission and Related Costs among Men Who Have Sex with Men: A Mathematical Modeling Study. PLoS One (2015) 0.75
The ABCs of Trait Anger, Psychological Distress, and Disease Severity in HIV. Ann Behav Med (2015) 0.75
Optimizing the Timing of HIV Screening as Part of Routine Medical Care. AIDS Patient Care STDS (2017) 0.75
Combinations of interventions to achieve a national HIV incidence reduction goal: insights from the agent-based PATH 2.0 model. AIDS (2017) 0.75
Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med (2007) 12.93
Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med (2003) 12.23
Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis (2008) 6.73
The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum Genet (2014) 6.69
Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI Study. PLoS Pathog (2013) 6.14
Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA (2008) 6.07
The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS (2010) 5.85
Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study. AIDS (2003) 5.61
When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study. Ann Intern Med (2011) 5.35
Short-course antiretroviral therapy in primary HIV infection. N Engl J Med (2013) 4.82
Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS (2007) 4.40
Prognosis of HIV-1-infected patients up to 5 years after initiation of HAART: collaborative analysis of prospective studies. AIDS (2007) 4.31
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection. N Engl J Med (2015) 4.26
Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Diabetes Care (2008) 4.10
Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet (2003) 3.84
HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis (2005) 3.77
Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study. BMJ (2011) 3.72
British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med (2008) 3.67
Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis (2011) 3.59
Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis (2005) 3.52
Factors associated with specific causes of death amongst HIV-positive individuals in the D:A:D Study. AIDS (2010) 3.47
An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med (2008) 3.42
The UCSC Cancer Genomics Browser: update 2011. Nucleic Acids Res (2010) 3.37
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up. J Infect Dis (2008) 3.35
Mortality in well controlled HIV in the continuous antiretroviral therapy arms of the SMART and ESPRIT trials compared with the general population. AIDS (2013) 3.30
Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis (2010) 3.30
The role of the Panton-Valentine leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis. Lancet Infect Dis (2012) 3.26
Effective therapy has altered the spectrum of cause-specific mortality following HIV seroconversion. AIDS (2006) 3.23
The temporal pattern of mortality responses to air pollution: a multicity assessment of mortality displacement. Epidemiology (2002) 3.21
Increasing prevalence of male homosexual partnerships and practices in Britain 1990-2000: evidence from national probability surveys. AIDS (2004) 3.17
Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch Intern Med (2012) 3.12
Methodology of the third British National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Sex Transm Infect (2013) 3.08
First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis (2011) 3.04
Population-based HIV-1 incidence in France, 2003-08: a modelling analysis. Lancet Infect Dis (2010) 3.01
Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest (2009) 2.92
Acute effects of ozone on mortality from the "air pollution and health: a European approach" project. Am J Respir Crit Care Med (2004) 2.89
Scale-free networks and sexually transmitted diseases: a description of observed patterns of sexual contacts in Britain and Zimbabwe. Sex Transm Dis (2004) 2.75
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. J Infect Dis (2005) 2.73
Considerations in the rationale, design and methods of the Strategic Timing of AntiRetroviral Treatment (START) study. Clin Trials (2012) 2.71
Predicting the risk of cardiovascular disease in HIV-infected patients: the data collection on adverse effects of anti-HIV drugs study. Eur J Cardiovasc Prev Rehabil (2010) 2.70
Ethnic variations in sexual behaviour in Great Britain and risk of sexually transmitted infections: a probability survey. Lancet (2005) 2.64
The gibberellin pathway mediates KNOTTED1-type homeobox function in plants with different body plans. Curr Biol (2002) 2.61
Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis (2013) 2.60
Increased HIV incidence in men who have sex with men despite high levels of ART-induced viral suppression: analysis of an extensively documented epidemic. PLoS One (2013) 2.55
KNOX action in Arabidopsis is mediated by coordinate regulation of cytokinin and gibberellin activities. Curr Biol (2005) 2.54
Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ (2005) 2.51
Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS (2009) 2.50
Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med (2013) 2.49
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count. AIDS (2007) 2.47
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS (2005) 2.45
Sexual risk behaviour and knowledge of HIV status among community samples of gay men in the UK. AIDS (2008) 2.43
Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data. Lancet (2007) 2.37
Missed opportunities for earlier HIV diagnosis within primary and secondary healthcare settings in the UK. AIDS (2008) 2.34
Air pollution and health: a European and North American approach (APHENA). Res Rep Health Eff Inst (2009) 2.33
High HIV incidence among MSM prescribed postexposure prophylaxis, 2000-2009: indications for ongoing sexual risk behaviour. AIDS (2012) 2.29
Response to combination antiretroviral therapy: variation by age. AIDS (2008) 2.28
Impact on life expectancy of HIV-1 positive individuals of CD4+ cell count and viral load response to antiretroviral therapy. AIDS (2014) 2.27
Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort. Clin Infect Dis (2009) 2.26
Estimating the exposure-response relationships between particulate matter and mortality within the APHEA multicity project. Environ Health Perspect (2005) 2.25
British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012. HIV Med (2012) 2.24
The temporal pattern of respiratory and heart disease mortality in response to air pollution. Environ Health Perspect (2003) 2.22
Distinct genetic loci control plasma HIV-RNA and cellular HIV-DNA levels in HIV-1 infection: the ANRS Genome Wide Association 01 study. PLoS One (2008) 2.14
Sexual function problems and help seeking behaviour in Britain: national probability sample survey. BMJ (2003) 2.12
Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health. Clin Trials (2010) 2.10
Who has sex with whom? Characteristics of heterosexual partnerships reported in a national probability survey and implications for STI risk. Int J Epidemiol (2008) 2.06
HIV-associated central nervous system diseases in the recent combination antiretroviral therapy era. Eur J Neurol (2010) 2.06
CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis (2006) 2.02
Reduced bone mineral density in HIV-infected patients: prevalence and associated factors. AIDS (2008) 2.01
Systems analysis of sex differences reveals an immunosuppressive role for testosterone in the response to influenza vaccination. Proc Natl Acad Sci U S A (2013) 2.00
Counterfactual links to the proportion of treatment effect explained by a surrogate marker. Biometrics (2005) 1.98
The changing incidence of AIDS events in patients receiving highly active antiretroviral therapy. Arch Intern Med (2005) 1.97
Acute effects of ambient particulate matter on mortality in Europe and North America: results from the APHENA study. Environ Health Perspect (2008) 1.93
The contribution of steady and casual partnerships to the incidence of HIV infection among homosexual men in Amsterdam. AIDS (2003) 1.93
CD8+ T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol (2004) 1.93
The prevalence of unplanned pregnancy and associated factors in Britain: findings from the third National Survey of Sexual Attitudes and Lifestyles (Natsal-3). Lancet (2013) 1.91